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Artemisinin combination therapy (ACT)
has revolutionised malaria treatment.
ACTs combine an artemisinin derivative
(a relatively new group of very effective
drugs [1]) with another longer-lasting drug
from another class to try to reduce the risk
of further resistance developing. ACTs cure
over 90% of people; they also act against
malaria gametocytes, so potentially reduce
transmission [1].
In 2006, the World Health Organization
(WHO) recommended ACTs for uncom-
plicated Plasmodium falciparummalaria world-
wide [2]. In 2010, the WHO added
dihydroartemisinin-piperaquine (DHA-PPQ)
to their existing list of four recommended
ACTs (that is, artemether-lumefantrine,
artesunate-amodiaquine, artesunate-mefloquine,
and artesunate-sulfadoxine-pyrimethamine).
DHA-PPQ is clearly at least as good as
existing options, and it has a simple dosing
schedule of one dose daily for three days
[3,4].
Dosing Bands in Children
One problem with DHA-PPQ is that the
drug ratio between the two components is
not ideal, because the level of DHA in the
fixed-dose product that has received regu-
latory approval is probably too low [5]. In
addition, the approved weight-based sched-
ules mean that some children may not
receive the WHO-specified minimum daily
doses of either drug, depending on whether
a child’s weight is close to the upper cut-off
for a particular dose category. Thus, some
children do not receive the minimum daily
dose set for PPQ, which has a narrower
therapeutic index, whereas some children
receive a dose very close to the minimum
daily dose for DHA. Indeed, a higher
DHA:PPQ ratio in the formulation would
have reduced the under-dosing with DHA,
which has a much wider therapeutic index
anyway.
These dosing problems related to the
ratio of components and the weight cut-offs
for whole and half tablet dosing are not the
only challenges with getting children the
appropriate antimalarial treatment. Whilst
clinical trials carefully weigh children and
dose them accordingly, most routine health
clinics use age to determine the dose. Since
the relationship between weight and age
varies among children and localities, this
increases the chances of under-dosing [6].
Children are growing rapidly at this time,
so age is rounded down, and this risk is
further increased. This problem is further
complicated by questions raised about dose
in a pharmacokinetic study in young
children from Burkina Faso, suggesting
that PPQ levels in younger children reach
lower concentrations for a given dose per
kilogram, indicating that children may
need a higher PPQ dose relative to adults
[7]. Specialists are concerned because
earlier work has shown that lower plasma
levels of PPQ are clearly associated with
increased risk of failure [8].
Dose and Failed Treatment
An individual patient data-level meta-
analysis by Ric Price and colleagues [9] in
this week’s PLOS Medicine provides substan-
tially new information about the extent of
the dosing problem and its consequences.
The authors pooled data from 26 trials
across more than 7,000 participants and
were able, using data from trial arms
receiving DHA-PPQ, to estimate that the
percentage of children whose total PPQ
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dose fell below WHO recommended lower
limits was about 29%. This high rate of
under-dosing occurred even under the ideal
conditions of carefully managed controlled
trials using predominantly weight-based
schedules. After adjusting for confounders,
the mg/kg dose of PPQ was shown to be a
significant predictor for recrudescence.
Although the actual absolute cure rates
are still above 90%, treating malaria on a
wide scale with suboptimal doses of anti-
malarial drugs with associated treatment
failure is likely to contribute to selection and
spread of drug-resistant parasites.
Methods Innovation
The analysis by Price and colleagues is
impressive and appropriate to the question
being tackled. The word ‘‘meta-analysis’’
and randomised controlled trials usually
implies relative differences between ran-
domised groups, but this study is different.
Here the authors have brought together
the individual data from comparative and
non-comparative trials, and analysed the
outcomes—mostly measures of cure—in
relation to risk factors, such as age, malaria
endemicity, and dose of drug per kilogram
of body weight. The authors ignore the
randomisation and analyse the data as an
observational dataset. This is different to
conventional analysis of the randomised
comparisons. In the work of the Cochrane
Infectious Diseases Group inmalaria (which
I co-ordinate), we have been preparing and
updating reviews of malaria since the mid -
1990s. We are able to give robust messages
that guide policy, but we observe substan-
tive quantitative heterogeneity between
trials that is not explained by subgroup
analysis. This does not impair the conclu-
sions about comparative effects, but leaves
us wondering how to get to grips with all the
factors—dose, host immunity, parasite drug
resistance—that might influence the abso-
lute cure rate. By analysing trial arms
observationally, Price and colleagues can
examine patient factors and directly relate
this to individual outcomes. This is innova-
tive and useful, drawing on the rigor of the
trial design in standardising data collection,
and is complementary to existing efforts.
Substantial Effort
This individual patient data analysis
represents an early and important output
of the Worldwide Antimalarial Resistance
Network (WWARN). This global network
was initially set up to monitor drug resis-
tance, but the opportunities to explore risk
factors for treatment failure, such as dose (as
in Price et al.), are now becoming obvious.
To do this, the investigators have had to set
up formal data-sharing legal agreements
with all the investigators carrying out
malaria trials, and to agree on standard
outcomes, measurements, and procedures.
It is not surprising this network has taken
some years to establish, and the extensive,
formal collaboration between researchers is
impressive.
Creation of the network has been helped
by the establishment, some years ago, of
fairly standard efficacy outcomes across
malaria trials. However, adverse event
detection and reporting has generally not
been standardised between trials; it is often
done badly and to date has not been part of
WWARN’s brief. Likely as a result, while
Price and colleagues report on gastrointes-
tinal toxicity, it is not clear if the data were
simply tolerability data collected in efficacy
trials to make sure everyone got an ade-
quate dose or formal adverse event data
collection, and over half the trials do not
contribute to this analysis. Nevertheless,
this is less a problem with WWARN and
more a generic problem due to the lack of
adverse event standardisation between trials
in malaria—and probably more generally.
However, if the Network and analyses of this
type are going to examine dose optimisation,
then standardising the collection and re-
porting of and rare adverse events, includ-
ing cardiotoxicity, will be important.
What’s Next?
There is no doubt that some dose
optimisation is required, and dosing
schedules will need to be changed so that
children at the lower end of the dosing
band per kilogram receive optimal doses.
This dosing adjustment will require careful
collection of toxicity and adverse event
data, and one trial is currently recruiting
to do this [10]. Furthermore, optimising
dosing does not take into account the
translation from weight- to age-based dosing
bands for programmatic implementation.
An additional consideration is that some
advocates are promoting programmes that
treat everyone in a population for malaria
(or test everyone and treat those positive)
to attempt to eradicate malaria [11]. If
DHA-PPQ is an option for these policies,
then getting the dose right is particularly
important. There is a balancing act
between under-dosing, which increases
the risk of resistance developing, and
increasing dosing, such that toxicity and
adverse events increase. This trade-off is
particularly important for mass treatment
of whole populations because the drug is
being used to treat children who may not
even be infected, so the benefit–risk
balance is different than when treating
sick children.
More broadly, this is not the first time
that under-dosing in children has been
shown to be a problem associated with
fixed-dose combinations: in 2006, WHO
revised its dosing for ethambutol for the
treatment of tuberculosis, which led to a
change in recommendations for the fixed-
dose combination product [12]. Research-
ers need to focus on age-based dosing and
the practical problems with banding.
Better attention to dosing and formulation
early in the drug development cycle, as
well as considering how this then translates
to age-based dosing schedules, are impor-
tant to ensure that children are cured,
adverse effects are avoided, and drug
resistance is prevented as much as possi-
ble. After all, this was the starting point for
developing ACTs.
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